Status:

COMPLETED

Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis

Lead Sponsor:

Aclaris Therapeutics, Inc.

Conditions:

Atopic Dermatitis

Eligibility:

All Genders

18-60 years

Phase:

PHASE2

Brief Summary

This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.

Detailed Description

This open-label, single-arm study of ATI-2138 in moderate to severe AD participants between the ages of 18 and 60 years (inclusive) will investigate the safety, tolerability, pharmacokinetics, efficac...

Eligibility Criteria

Inclusion

  • Able to comprehend and willing to sign the IRB approved ICF/assent prior to administration of study-related procedures.
  • Male patients or non-pregnant, non-nursing female patients 18 to 60 years old, inclusive, at the time of informed consent/assent.
  • Have at least a 1-year history of moderate or severe AD prior to the Screening Visit, and no significant AD flares for the 4 weeks prior to the Screening Visit as determined by the Investigator upon review of participant medical history.

Exclusion

  • Any prior exposure to systemic (oral) JAK inhibitors or TYK inhibitors at any time prior to Screening.
  • Unstable course of AD (spontaneously improving or rapidly deteriorating) based on the patient history or as determined by the investigator during the Screening Period.
  • Refractory AD (ie, AD that required frequent hospitalizations and/or frequent intravenous treatment for skin infections within the year before the Screening Visit).
  • Concomitant skin disease or clinically infected AD or presence of other skin disease in the area to be dosed that may interfere with study assessments.
  • Female patients who are pregnant, nursing, or planning to become pregnant during the study.

Key Trial Info

Start Date :

August 19 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 27 2025

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT06585202

Start Date

August 19 2024

End Date

March 27 2025

Last Update

April 29 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Aclaris Investigational Site

Birmingham, Alabama, United States, 35244

2

Aclaris Investigational Site

Encino, California, United States, 91436

3

Aclaris Investigational Site

San Diego, California, United States, 92123

4

Aclaris Investigational Site

Plainfield, Indiana, United States, 46168